Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.80
Bid: 29.00
Ask: 30.70
Change: -0.90 (-2.93%)
Spread: 1.70 (5.862%)
Open: 28.80
High: 29.80
Low: 28.80
Prev. Close: 30.70
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DiaSpect Tm McKesson US distribution agreement

9 Aug 2018 07:00

RNS Number : 2695X
EKF Diagnostics Holdings PLC
09 August 2018
 

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

DiaSpect Tm US distribution agreement with McKesson

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has signed a private label distribution agreement with McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation - the Fortune Global 500 healthcare distribution specialist and one of the largest companies in the US by revenue - for the Company's hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm.

 

The DiaSpect Tm is the world's fastest hemoglobin analyzer and will be branded in the US by McKesson under its own branded line, as the McKesson Consult® Hb analyzer.

 

The agreement follows US Food and Drug Administration 510(k) clearance and CLIA waiver by statute for the DiaSpect Tm in April 2018, approving the product for use in point of care and Certificate of Waiver settings. Sales of the McKesson Consult® Hb analyzer are expected following full launch in the autumn, 2018.

 

For more information on the DiaSpect Tm see: www.ekfdiagnostics.com/diaspect.html 

 

Commenting, Julian Baines, CEO of EKF, said:  

"As I said in April the US market is a key target for the DiaSpect Tm, which gives physicians access to an easy to use, accurate and portable hemoglobin measurement system able to deliver laboratory quality results at the point of care within seconds." 

 

"This agreement with McKesson allows us to offer this innovative technology to physicians and childcare specialists across the US through the market's leading and most established healthcare distribution player. We expect that this partnership will ultimately deliver significant value to shareholders."

 

 

Enquiries:

 

EKF Diagnostics Holdings plc 

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Aubrey Powell / Shaun Dobson

Walbrook PR Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About McKesson Medical-Surgical mms.mckesson.com

McKesson Medical-Surgical Inc. is an affiliate of the McKesson Corporation. McKesson Corporation, currently ranked 6th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson Medical-Surgical works with health systems, physician offices, extended care providers, in-home patients, labs, payers and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson Medical-Surgical helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.

About EKF Diagnostics Holdings plc www.ekfdiagnostics.com

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRDDGDIRBGBGII
Date   Source Headline
4th Mar 20207:00 amRNSNotice of Results
24th Feb 20201:56 pmRNSHolding(s) in Company
29th Jan 20207:00 amRNSTrading update
6th Nov 201912:14 pmRNSTrading update and performance bonuses
10th Sep 20197:00 amRNSHalf-year Report
10th Sep 20197:00 amRNSPreferred Partner Arrangement with Mount Sinai
21st Aug 20197:00 amRNSNotice of Results
8th Aug 20194:40 pmRNSSecond Price Monitoring Extn
8th Aug 20194:35 pmRNSPrice Monitoring Extension
15th Jul 20197:00 amRNSTrading update
11th Jun 20192:15 pmRNSCancellation of share options
7th Jun 20194:30 pmRNSHolding(s) in Company
28th May 20197:00 amRNSDirector/PDMR Shareholding
2nd May 201911:21 amRNSResult of AGM
26th Apr 20196:20 pmRNSAcquisition of further interest in Renalytix AI
25th Apr 20197:00 amRNSPosting of AR & Accounts and Notice of AGM
13th Mar 20197:00 amRNSFinal Results
8th Mar 20197:00 amRNSNotice of Results
20th Feb 20197:00 amRNSUS FDA approval for Quo-Test analyser
22nd Jan 20197:00 amRNSUpdate on McKesson US distribution agreement
21st Jan 20197:00 amRNSClarification re. lock-up restrictions
16th Jan 20197:00 amRNSTrading update
20th Dec 20187:00 amRNSUpdate regarding planned change of NOMAD
19th Dec 20184:56 pmRNSPDMR dealing
7th Dec 20183:15 pmRNSPurchase of own shares and PDMR Dealing
30th Nov 20182:35 pmRNSTotal Voting Rights
22nd Nov 20185:13 pmRNSPurchase of own shares and PDMR Dealing
21st Nov 20182:08 pmRNSPurchase of own shares and PDMR Dealing
20th Nov 20185:18 pmRNSPurchase of own shares and PDMR Dealing
14th Nov 20182:20 pmRNSShare Buy-Back
9th Nov 20181:48 pmRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSRENX Admission to AIM and First Day of Dealings
2nd Nov 20188:00 amRNSSchedule 1 update - Renalytix AI plc
1st Nov 20185:30 pmRNSUpdate regarding AIM admission of RenalytixAI
31st Oct 20186:00 pmRNSResult of RO by RenalytixAI & Fundraising Update
23rd Oct 20182:00 pmRNSSchedule One Update - Renalytix AI plc
23rd Oct 201811:01 amRNSUpdate to distribution timetable
22nd Oct 20185:23 pmRNSApproval of distribution of shares in RenalytixAI
19th Oct 201812:10 pmRNSResult of General Meeting
19th Oct 201811:00 amRNSSchedule One - Renalytix AI plc
12th Oct 20187:00 amRNSInvestor presentation
11th Oct 20186:03 pmRNSLaunch of Restricted Offer by Renalytix AI plc
11th Oct 20185:21 pmRNSFundraising and AIM admission of Renalytix AI plc
11th Oct 20184:01 pmRNSFundraising and AIM admission of Renalytix AI plc
27th Sep 201810:15 amRNSNotice of GM
19th Sep 20187:00 amRNSHalf-year Report
17th Sep 201812:21 pmRNSNotice of Results
31st Aug 20182:00 pmRNSUpdate regarding proposed IPO of Renalytix AI
16th Aug 20187:00 amRNSHolding(s) in Company
9th Aug 20187:14 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.